SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
N Engl J Med
.
2022 Jun 23;386(25):2436-2438.
doi: 10.1056/NEJMc2202861.
Epub 2022 Jun 8.
Authors
Erin M Scherer
1
,
Ahmed Babiker
1
,
Max W Adelman
1
,
Brent Allman
1
,
Autum Key
1
,
Jennifer M Kleinhenz
1
,
Rose M Langsjoen
1
,
Phuong-Vi Nguyen
1
,
Ivy Onyechi
1
,
Jacob D Sherman
1
,
Trevor W Simon
1
,
Hannah Soloff
1
,
Jessica Tarabay
2
,
Jay Varkey
3
,
Andrew S Webster
3
,
Daniela Weiskopf
4
,
Daniel B Weissman
5
,
Yongxian Xu
5
,
Jesse J Waggoner
5
,
Katia Koelle
5
,
Nadine Rouphael
5
,
Stephanie M Pouch
5
,
Anne Piantadosi
5
Affiliations
1
Emory University, Atlanta, GA
[email protected]
.
2
Emory Healthcare, Atlanta, GA.
3
Emory University, Atlanta, GA.
4
La Jolla Institute for Immunology, La Jolla, CA.
5
Emory University, Atlanta, GA
[email protected]
.
PMID:
35675197
PMCID:
PMC9202319
DOI:
10.1056/NEJMc2202861
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Viral
Antigenic Drift and Shift
COVID-19*
Evolution, Molecular*
Humans
Immunocompromised Host
Neutralization Tests
SARS-CoV-2*
Substances
Antibodies, Viral
Grants and funding
UM1 AI148576/AI/NIAID NIH HHS/United States
K08 AI139348/AI/NIAID NIH HHS/United States
K08AI139348 (AP)/National Institute of Allergy and Infectious Diseases
contract No. 75N9301900065 (DW)/NH/NIH HHS/United States
75D30121C10084 under BAA ERR 20-15-2997 (AB, JW, K/CC/CDC HHS/United States
5UM1AI148576-02 (NR and EMS)/National Institute of Allergy and Infectious Diseases